HRP20000704B1 - Peroralni pripravci koji kontrolirano oslobađaju levosimendan - Google Patents

Peroralni pripravci koji kontrolirano oslobađaju levosimendan

Info

Publication number
HRP20000704B1
HRP20000704B1 HR20000704A HRP20000704A HRP20000704B1 HR P20000704 B1 HRP20000704 B1 HR P20000704B1 HR 20000704 A HR20000704 A HR 20000704A HR P20000704 A HRP20000704 A HR P20000704A HR P20000704 B1 HRP20000704 B1 HR P20000704B1
Authority
HR
Croatia
Prior art keywords
levosimendan
control
controlled manner
oral preparations
controlled release
Prior art date
Application number
HR20000704A
Other languages
English (en)
Croatian (hr)
Inventor
Larma Ilkka
Backman Maarit
Antila Saila
Lehtonen Lasse
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8551575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20000704(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of HRP20000704A2 publication Critical patent/HRP20000704A2/hr
Publication of HRP20000704B1 publication Critical patent/HRP20000704B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
HR20000704A 1998-04-23 1999-04-23 Peroralni pripravci koji kontrolirano oslobađaju levosimendan HRP20000704B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI980901A FI980901A7 (fi) 1998-04-23 1998-04-23 Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
PCT/FI1999/000329 WO1999055305A2 (en) 1998-04-23 1999-04-23 Controlled release peroral compositions of levosimendan

Publications (2)

Publication Number Publication Date
HRP20000704A2 HRP20000704A2 (en) 2001-04-30
HRP20000704B1 true HRP20000704B1 (hr) 2009-11-30

Family

ID=8551575

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000704A HRP20000704B1 (hr) 1998-04-23 1999-04-23 Peroralni pripravci koji kontrolirano oslobađaju levosimendan

Country Status (37)

Country Link
US (1) US7045147B1 (enExample)
EP (1) EP1071397B1 (enExample)
JP (2) JP4566402B2 (enExample)
KR (1) KR100960597B1 (enExample)
CN (1) CN1248691C (enExample)
AR (1) AR019096A1 (enExample)
AT (1) ATE258425T1 (enExample)
AU (1) AU756641B2 (enExample)
BG (1) BG64839B1 (enExample)
BR (1) BR9909869A (enExample)
CA (1) CA2329234C (enExample)
CO (1) CO5070607A1 (enExample)
CZ (1) CZ295194B6 (enExample)
DE (1) DE69914472T2 (enExample)
DK (1) DK1071397T3 (enExample)
EA (1) EA002829B1 (enExample)
EE (1) EE04220B1 (enExample)
ES (1) ES2215379T3 (enExample)
FI (1) FI980901A7 (enExample)
GE (1) GEP20032906B (enExample)
HR (1) HRP20000704B1 (enExample)
HU (1) HUP0101458A3 (enExample)
ID (1) ID27987A (enExample)
IL (2) IL138951A0 (enExample)
MX (1) MXPA00010367A (enExample)
NO (1) NO329809B1 (enExample)
NZ (1) NZ507453A (enExample)
PL (1) PL197447B1 (enExample)
PT (1) PT1071397E (enExample)
RS (1) RS49962B (enExample)
SI (1) SI1071397T1 (enExample)
SK (1) SK285427B6 (enExample)
TR (1) TR200003102T2 (enExample)
TW (1) TWI224507B (enExample)
UA (1) UA68376C2 (enExample)
WO (1) WO1999055305A2 (enExample)
ZA (1) ZA200005632B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011465A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Pyridatsinonijohdannaisen uusi käyttö
BRPI0408323A (pt) * 2003-03-14 2006-03-07 Nirmal Mulye processo para a preparação de compimidos de liberação prolongada
FI20070521A7 (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383449A2 (en) * 1989-02-11 1990-08-22 Orion-Yhtymà„ Oy Pyridazinone derivatives and processes for preparing the same
WO1992012135A1 (en) * 1991-01-03 1992-07-23 Orion-Yhtymä Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile
WO1993021921A1 (en) * 1992-05-06 1993-11-11 Orion-Yhtymä Oy Anti-ischemic medicament
WO1999016443A1 (en) * 1997-09-26 1999-04-08 Orion Corporation Oral compositions of levosimendan

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203684A (en) 1982-04-05 1986-06-11 Merck Sharp & Dohme Granular formulation for the stabilization of unstable drugs or food supplements
US4716042A (en) 1986-06-16 1987-12-29 American Home Products Corporation Stabilized coated aspirin tablets
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI974578L (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383449A2 (en) * 1989-02-11 1990-08-22 Orion-Yhtymà„ Oy Pyridazinone derivatives and processes for preparing the same
WO1992012135A1 (en) * 1991-01-03 1992-07-23 Orion-Yhtymä Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile
WO1993021921A1 (en) * 1992-05-06 1993-11-11 Orion-Yhtymä Oy Anti-ischemic medicament
WO1999016443A1 (en) * 1997-09-26 1999-04-08 Orion Corporation Oral compositions of levosimendan

Also Published As

Publication number Publication date
SK15542000A3 (sk) 2001-08-06
WO1999055305A2 (en) 1999-11-04
ATE258425T1 (de) 2004-02-15
GEP20032906B (en) 2003-02-25
CZ20003780A3 (en) 2001-05-16
UA68376C2 (en) 2004-08-16
TWI224507B (en) 2004-12-01
ES2215379T3 (es) 2004-10-01
YU63900A (sh) 2003-07-07
MXPA00010367A (es) 2002-06-04
RS49962B (sr) 2008-09-29
AU3524699A (en) 1999-11-16
SI1071397T1 (en) 2004-06-30
BG104959A (en) 2001-07-31
HUP0101458A3 (en) 2002-05-28
US7045147B1 (en) 2006-05-16
SK285427B6 (sk) 2007-01-04
HUP0101458A2 (hu) 2002-03-28
EP1071397B1 (en) 2004-01-28
CA2329234A1 (en) 1999-11-04
HRP20000704A2 (en) 2001-04-30
AU756641B2 (en) 2003-01-16
PL197447B1 (pl) 2008-03-31
CN1301163A (zh) 2001-06-27
NO329809B1 (no) 2010-12-20
PT1071397E (pt) 2004-06-30
JP4566402B2 (ja) 2010-10-20
ID27987A (id) 2001-05-03
CA2329234C (en) 2008-06-10
PL344078A1 (en) 2001-09-24
EE04220B1 (et) 2004-02-16
EA002829B1 (ru) 2002-10-31
FI980901A7 (fi) 1999-10-24
IL138951A (en) 2006-10-31
KR20010071172A (ko) 2001-07-28
JP2002512946A (ja) 2002-05-08
DE69914472T2 (de) 2004-11-11
BG64839B1 (bg) 2006-06-30
WO1999055305A3 (en) 1999-12-29
JP2010083900A (ja) 2010-04-15
EA200001098A1 (ru) 2001-04-23
NO20005313D0 (no) 2000-10-20
IL138951A0 (en) 2001-11-25
EE200000617A (et) 2002-06-17
BR9909869A (pt) 2000-12-19
CZ295194B6 (cs) 2005-06-15
KR100960597B1 (ko) 2010-06-07
TR200003102T2 (tr) 2001-02-21
FI980901A0 (fi) 1998-04-23
EP1071397A2 (en) 2001-01-31
HK1034032A1 (en) 2001-10-12
NZ507453A (en) 2003-02-28
NO20005313L (no) 2000-11-21
ZA200005632B (en) 2002-01-14
CO5070607A1 (es) 2001-08-28
DK1071397T3 (da) 2004-04-05
DE69914472D1 (de) 2004-03-04
CN1248691C (zh) 2006-04-05
AR019096A1 (es) 2001-12-26

Similar Documents

Publication Publication Date Title
YU49495B (sh) Formulacije oksikodona sa kontrolisanim otpuštanjem i njihova upotreba
AU1534699A (en) Osmotic dosage form comprising first and second coats
MY130765A (en) Oral pharmaceutical pulsed release dosage form
NO971206D0 (no) Forlenget-frigjöringsformulering
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
GB0007419D0 (en) Composition
ATE427103T1 (de) Orale verabreichung von adenosin analogen
DK0871748T3 (da) Indgivelse af biologisk aktive polypeptider
NO931766D0 (no) Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin
YU49354B (sh) Oralne tečne formulacije alendronata
DE69613463D1 (de) Filmbildende pharmazeutische zusammensetzungen zur transdermalen verabreichung
ATE324872T1 (de) Orale pharmazeutische zusammensetzung mit verzögerter wirkstofffreigabe von protonenpumpen- hemmern
DK0959888T3 (da) Anvendelse af det chelerende middel clioquinol til fremstillingen af et farmaceutisk præparat til behandlingen af Alzheimer's sygdom
WO1994027589A3 (en) Antidepressant dosage form
AU5267698A (en) Ascending-dose dosage form
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
BG104397A (en) Extended release formulation
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
HRP20000704B1 (hr) Peroralni pripravci koji kontrolirano oslobađaju levosimendan
AR021159A1 (es) Composiciones orales de 8-cloro-6,11-dihidro-11-(4-piperidilidin)-5h-benzo[5,6]-ciclohepta[1,2-b]piridina

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100412

Year of fee payment: 12

PBON Lapse due to non-payment of renewal fee

Effective date: 20110424